New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:24 EDTECYTEndocyte shares can advance even if NSLC treatment fails, says RBC Capital
RBC Capital is upbeat on Endocyte's pipeline and believes that the company's long-term fundamentals have improved. The firm thinks the stock's risk/reward ratio is positive at current levels and keeps an Outperform rating on the shares.
News For ECYT From The Last 14 Days
Check below for free stories on ECYT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ECYT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use